Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Reduces Brain Damage after Stroke in the Neonatal Mouse Brain.

Area of Science:

• Neuroscience
• Cerebrovascular Research
• Pharmacology

Background:

• Neonatal ischemia can cause significant long-term neurological deficits.
• The poly(ADP-ribose) polymerase inhibitor PJ34 has shown potential in enhancing cerebral blood flow.
• Understanding the effects of PJ34 on the neurovascular unit after neonatal stroke is crucial.

Purpose of the Study:

• To investigate the therapeutic benefits of PJ34 in a neonatal mouse model of ischemic stroke.
• To assess the impact of PJ34 on cerebral hemodynamics, blood-brain barrier integrity, and glial cell responses.

Main Methods:

• Neonatal mice underwent permanent middle cerebral artery occlusion (pMCAo) and received either PJ34 or PBS treatment.
• Cerebral blood flow was measured using Doppler-ultrasonography.
• Blood-brain barrier opening, astrocyte survival, and lesion volume were evaluated at various time points post-ischemia.

Main Results:

• PJ34 administration prevented the drop in cerebral blood flow in the ipsilesional internal carotid artery (ICA) and increased flow in the contralesional ICA.
• PJ34 treatment reduced blood-brain barrier disruption and astrocyte demise in the rostral brain regions.
• While PJ34 reduced lesion areas in specific rostral territories, overall total tissue loss was not significantly altered.

Conclusions:

• PJ34 demonstrates neuroprotective effects following neonatal ischemic stroke by improving hemodynamics and preserving the blood-brain barrier.
• The drug's benefits appear localized to rostral brain areas, suggesting a role for anterior ICA collateral supply.
• Further research is warranted to explore PJ34's full therapeutic potential in neonatal stroke.